Peggy L. Carver, PharmD, FCCP Page 1 of 30
Curriculum Vitae
PEGGY L. CARVER, PHARM.D, FCCP
June, 2014
University of Michigan College of Pharmacy
428 Church Street
Ann Arbor, MI 48109-1065
(734) 764-9384 (phone)
(734) 763-2022 (FAX)
Email:
EDUCATION
1983Doctor of Pharmacy
University of California
School of Pharmacy
San Francisco, CA
1979BA Biology (Honors)
University of California
Los Angeles, CA
PROFESSIONAL EXPERIENCE
1994-presentAssociate Professor of Pharmacy (with tenure)
University of MichiganCollege of Pharmacy
Aug 1997-Feb 1998Visiting Research Scientist
Merck Research Laboratories
Rahway, New Jersey
[sabbatical leave spent in molecular biology laboratory; cloning Candida genes under the direction of Myra Kurtz, PhD, Rosemary Kelly, Ph.D. and John Kozarich, Ph.D.]
Feb 1998-Sept 1998Visiting Research Scientist:
Universitat Westfälisch, Münster Germany
Université de Paris Sud, Orsay, France
Université de Grenoble, Grenoble, France
[sabbatical leave]
1986-1994Assistant Professor of Pharmacy
University of MichiganCollege of Pharmacy
Ann Arbor, MI
1986-presentClinical Pharmacist
Adult Infectious Diseases Service
University of MichiganMedicalCenter
Ann Arbor, MI
1986-2005Program Director, Advanced Residency in Infectious Diseases
University of MichiganMedicalCenter
Ann Arbor, MI
1984-1986Post Doctoral Pharmacy Fellow
Infectious Diseases Practice & Research
Department of Pharmacy Services
HartfordHospital
Hartford, CT
Assistant Clinical Professor of Pharmacy
University of ConnecticutSchool of Pharmacy
Storrs, CT
1983-1984Clinical Pharmacy Resident
University of California, San Francisco
San Francisco, CA
HONORS AND AWARDS
2013P3 Class Recognition award
2011Phi Delta Chi Brother of the Month, December 2011
2011Nominee, Outstanding Student Group Advisor at the University of Michigan
2011, 2012, 2013, 2014Nominee, Outstanding Advisor, Phi Delta Chi Fraternity
2010Outstanding Poster, ESPEN 2010, Nice, France. September 2010
2010Teaching Excellence Award, UM College of Pharmacy
2010Student Appreciation Award from 3rd year class, UM College of Pharmacy
2010Phi Delta Chi Brother of the Month, April 2010
2009Phi Delta Chi "outstanding faculty" graduate brother
2008Teaching Excellence Award, Nominee, UM College of Pharmacy
2007Best Poster, MAD 2007 Infectious Diseases Conference
2006Fellow, AmericanCollege of Clinical Pharmacy
2006Preceptor of the Year, Nominee, UM College of Pharmacy
2005Teaching Excellence Award, Nominee, UM College of Pharmacy
2004Teaching Excellence Award, Nominee, UM College of Pharmacy
2003Teaching Excellence Award, Nominee, UM College of Pharmacy
2002Best Poster, Nominee, ACCP Spring Meeting, SavannahGA
2002Teaching Excellence Award, Nominee, UM College of Pharmacy
2001Teaching Excellence Award, Nominee, UM College of Pharmacy
2000Teaching Excellence Award, Nominee, UM College of Pharmacy
1990Student Research Preceptor Award
Southeastern Michigan Society of Hospital Pharmacists
1983Rho Chi Honor Society, Initiate
University of California, San FranciscoSchool of Pharmacy
1983Bowl of Hygeia Award, Nominee
University of California, San FranciscoSchool of Pharmacy
1981Barnes Hind Scholarship
University of California, San FranciscoSchool of Pharmacy
1979Graduation with honors
University of California, Los Angeles
1979Chancellor's Marshall
University of California, Los Angeles
1975National Merit Commended Student
PROFESSIONAL ACTIVITIES
Positions Held
2014Frontiers in Infectious, member of Review Editorial Board
2013-presentACCP Student Liaison
2012Expert Reviewer, Ambulatory Care Self-Assessment Program (ACSAP) for the American College of Clinical Pharmacy
2011, 2012Member, “TIPS” Teaching Innovation Prize” selection committee, University of Michigan
2009-presentAdvisor, Phi Delta Chi Fraternity, Alpha Chapter (University of Michigan)
2013Our chapter won multiple awards, including 100 percent in achievement award points; third place in the brotherhood report; and 10th for the Emory W. Thurston Grand President’s Award, the highest ranking that the chapter has achieved since its reactivation in 2004.
2011Of 88 chapters nationwide, Alpha chapter was ranked nationally as 10thoverallfor the Emory W. Thurston Grand President’s Award(the highest award in the fraternity), 8thnationallyfor the John D. Grabenstein Leadership award, 3rd nationallyfor the Ralph Saroyan Brotherhood Award and 17th for Scholarship, 13th for the professional and service project, and 28th for the window display.
2011Phi Delta Chi was awarded the Michigan LeadershipAward for Outstanding Student Organization 2011; this is a competitive award at theUniversity of Michigan Campus of all student organizations (1000+ total).
2011Of 88 chapters nationwide, Alpha chapter was ranked nationally as: 7th for the Emory W. Thurston Grand President’s Award(the highestaward in the fraternity and the highest ranking since chapter reactivation in 2004),4thnationallyfor the John D. Grabenstein Leadership award, 3rd nationallyfor the Ralph Saroyan Brotherhood Award and Desmet Scholarship, 2nd nationally for the Scrapbook award, and received the Dale W. Doerr Achievement Award
2012Nominated for University of Michigan Philanthropy Award
2009-presentMember, SIDP Newsletter committee
2008-presentReviewer, Up to Date
2006Reviewer, ACCP ID-PRN ID Mini-sabbatical grant review committee
2006-presentMember, Past-President’s Advisory Committee (SIDP)
2005-2007Member, ACCP 2007 Annual Program Committee
2004-2005Member, Elections Committee,SIDP
2005-presentMember, Editorial Board, Reviewson Recent Clinical Trials
2004Member, ACCP ID-PRN ID Fungal bibliography committee
2001-2002Past-President, Society of Infectious Diseases Pharmacists (SIDP)
2000-2001President, Society of Infectious Diseases Pharmacists (SIDP)
2000-2002Member, ACCP 2002 Annual Program Committee
2001-2002Member, CRLT Advisory Board
2003Member, “Best Poster” committee, ACCP Annual Meeting
2002Chair, Abstract Reviews, ACCP 2002 Annual Program
2002Reviewer, PSAP IV, Self-Assessment Program(ACCP)
1999-2000President-Elect, SIDP
1999-2001Board Liaison and Member, Membership Committee, SIDP
1998-2000Board Member at Large, SIDP
(served only one year of 2 year term of office; due to election as
President-elect)
1997-200Member, Advisory Board, Pharmacoeconomics: Infectious Diseases
1997-2004Member, Membership Committee,SIDP
1996Reviewer, textbook proposal, Williams and Wilkins Inc.
1996-1998Member, Publications Committee,SIDP
1995-1998Member, NIH Study Section (SBIR)
1995-2000Data Safety Monitoring Board, Warner-Lambert Parke
Davis Pharmaceutical Company
1994-1999Member, Editorial Advisory Board, Journal of InfectiousDisease Pharmacotherapy
1994-1996Member, Awards Committee SIDP
1994-1996Member, Ad Hoc Finance Committee, SIDP
1993-1994Chair, American Society of Hospital Pharmacists
Specialty Practice Group in Infectious Diseases (SPG)
1992-1994Secretary-Treasurer, SIDP
1992-1993Vice-chair, American Society of Hospital Pharmacists
Specialty Practice Group in Infectious Diseases (SPG)
1991-1993Member, Annual Meeting Committee, SIDP
1990Reviewer, Clinical Pharmacology and Nursing,
Springhouse Corp., Springhouse, PA.
1987-1990Member, SE Michigan Society of Hospital Pharmacists Awards Committee
PROFESSIONAL AFFILIATIONS
American Association of Colleges of Pharmacy (AACP)
AmericanCollege of Clinical Pharmacy (ACCP)
AmericanCollege of Clinical Pharmacy ID-PRN
American Society of Health-System Pharmacists (ASHP)
American Society of Microbiology (ASM)
Immune Compromised Host Society (ICHS)
Infectious Diseases Society of America (IDSA)
International Pharmaceutical Federation
International Pharmaceutical Federation (FIP)
International Society for Human and Animal Mycology (ISHAM)
PhI Delta Chi Pharmacy Fraternity
Sigma Xi
Society of Infectious Diseases Pharmacists (SIDP)
Southeast Michigan Society of Health-System Pharmacists
Journal Reviewer
2014-presentReviewer, Journal of Clinical Pharmacology
2013-presentReviewer, BMC Infectious Diseases, Cancer Medicine
2013-presentReviewer, Cancer Medicine
2012-presentReviewer, Clinical Transplantation
2011-presentReviewer, Metallomics
2008-presentReviewer, Future Microbiology
2008-presentReviewer, Drugs
2007-presentReviewer, Pediatric Infectious Diseases
2007-presentReviewer, Biopharmaceutics & Drug Disposition
2007-presentReviewer, Applied and Environmental Microbiology
2006-presentReviewer, Therapeutics and Clinical Risk Management
2005-presentReviewer, Pharmacy Today
2005-presentReviewer, Mycoses
2005-presentReviewer, ExpertReview of Anti-Infective Therapy
2005-presentReviewer, ExpertOpinion on Pharmacotherapy
2005-presentReviewer, BMT
2004-presentReviewer, Journal of Clinical Microbiology
2004-presentReviewer, European Journal of Clinical Microbiology & Infectious Diseases
1998-presentReviewer, Journal of Pharmacy Technology
1994-presentReviewer, Inorganic Chemistry
1994-presentReviewer, Clinical Infectious Diseases
1993-presentReviewer, USP-DI
1993-presentReviewer, Antimicrobial Agents and Chemotherapy
1992-presentReviewer, Pharmacotherapy
1990-2006Reviewer, The Medical Letter
1989-presentReviewer, Hospital Pharmacy
1987-presentReviewer, The Annals of Pharmacotherapy
1986-presentReviewer, American Journal of Hospital Pharmacy
1986-1994Reviewer, Clinical Pharmacy
RESEARCH PUBLICATIONS
Quintiliani R, Carver PL, NightingaleCH. Comparative Pharmacokinetic Study of Cefotetan and Cefoxitin in Healthy Volunteers. In: Progress in the Treatment and Prevention of Polymicrobial Infections. Proceedings of the 14th International Congress of Chemotherapy. Kyoto, Japan. 1985.
Carver PL, Quintiliani R, Nightingale CH. Comparative Pharmacokinetics of Cefoxitin and Cefotetan in Healthy Volunteers. Inf in Surgery S3: 11-14, 1986.
Carver PL, Nightingale CH, Quintiliani R, Sweeney K, Stevens RC, Maderazo E. Pharmacokinetics of Single and Multiple Dose Teicoplanin in Healthy Volunteers. Antimicrob Agents Chemother 1989; 33(1)82-6.
Carver PL, Nightingale CH, Quintiliani R. Pharmacokinetics and Pharmacodynamics of Total and Unbound Cefoxitin and Cefotetan in Healthy Volunteers. Journal of Antimicrobial Chemotherapy 1989; 23: 99-106.
Guglielmo BJ, Salazar TA, Rodondi LC, Carver M, Goldstone J, Stoney RJ. Altered Pharmacokinetics of Antibiotics During Vascular Surgery. Am J Surgery 1989; 157(4): 410-2.
Colburn PA, Carver PA, Montgomery PA, Alaniz C, Chaffee BW, Amesbury BK. Appropriate but not Cost Effective Ceftazidime Use at a University Hospital. Hosp Pharm Nov 1989, 24:911-916.
Bleske BE, Carver PL, Annesley TM, Bleske JR, Morady F. The Effect of Ciprofloxacin on the Pharmacokinetic and ECG Parameters of Quinidine. J Clin Pharmacology 1990; 30(10): 911-915.
Knapp MJ, Berardi RR, Dressman JB, Rider JM, Carver PL. Modification of Gastric pH with Oral Glutamic Acid Hydrochloride. Clinical Pharmacy 1991;10:866-869.
Carver PL, Harris EM, Novak JC. Use of Computer Assisted Instruction to Review Microbiology and Antimicrobial Agents. Am J Pharmaceutical Education 1991;55(3):248-253.
Carver PL, Berardi RR, Knapp MJ, Rider JM, Kauffman CA, Bradley SF, Atassi M. In Vivo Interaction of Ketoconazole and Sucralfate in Healthy Volunteers. Antimicrobial Agents and Chemotherapy 1994; 38:326-29.
Hoeschele JD, Roy A, Pecoraro VL, Carver PL. In Vitro Analysis of Interaction Between Ketoconazole and Sucralfate. Antimicrobial Agents and Chemotherapy 1994; 38:319-25.
Welage LS, Carver PL. Antibacterial Activity of Sucralfate versus Aluminum Chloride in Simulated Gastric Fluid. European Journal of Clinical Microbiology 1994;13:1046-52.
Welage LS, Carver PL, Revankar S, Pierson C, Kauffman CA. Alterations in Gastric Acidity in Patients Infected with Human Immunodeficiency Virus. Clinical Infectious Diseases 1995;21:1431-38.
Cheng CL, Smith DE, Carver PL, Cox SR, Watkins PB, Blake DS, Kauffman CA, Meyer KM, Amidon GL, Stetson PL. Steady-State Pharmacokinetics of Delavirdine in HIV-Positive Patients: Effect on Erythromycin Breath Test. Clin Pharmacol Ther 1997;61:531-43.
Carver PL, Fleisher D, Ling C, Zhou SY, Kaul D, Kazanjian P, Li C. Meal Composition Effects on the Oral Bioavailability of Indinavir in HIV-infected patients. Pharmaceutical Research 1999, 16(5): 718-24.
Klepser ME, Lewis RE, Ernst EJ, Petzold CR, Bailey EM, Burgess DS, Carver PL, Lacy MK, Mercier RC, Nicolau DP, Zhanel GG, Pfaller MA. Multi-center evaluation of standardized methods for conducting antifungal time-kill studies. Journal of Infectious Disease Pharmacotherapy 2001;5(2):29-42.
Carver PL, Whang E, VandenBussche HL, KauffmanCA, Malani P. Risk Factors for Arthralgias or Myalgias associated with Quinupristin-Dalfopristin. Pharmacotherapy 2003: 23(2): 47-53.
DePestelDD, KazanjianP, Cinti S, KauffmanCA, Carver PL. Magnitude and Duration of Elevated Gastric pH in Patients Infected with Human Immunodeficiency Virus After Administration of Chewable, Dispersible, Buffered Didanosine Tablets. Pharmacotherapy 2004;24(11):1539–1545.
Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyk A, Kauffman CA. Candida glabrata fungemia: Experience in a tertiary care center. Clin Infect Dis 2005;41:975–81.
Carver, PL. Clinical Evaluation of Drug Interactions: Translation of Information from the Chemist’s Bench to the Patient’s Bedside. Journal of Biological Inorganic Chemistry (2007) 12 (Suppl 1):S7–S52, (published abstract, SL004).
Carver PL. Hepatic Safety of Concomitant Caspofungin and Cyclosporine. Submitted to Journal of Antimicrobial Chemotherapy.
Surowiec D, DePestel DD, Carver PL.Concurrent Use of Sirolimus and Voriconazole: a Pilot Study Assessing Safety and Approaches to Appropriate Management. Pharmacotherapy 2008;28(6):719–729.
Carver PL, Lin SW, DePestel DD,Newton DW. The Impact of mecA Gene Testing and Infectious Diseases Pharmacists’ Intervention on the Time to Appropriate Antimicrobial Therapy for Staphylococcus aureus Bacteremia at a UniversityHospital.Journal of Clinical Microbiology 2008;46:7: 2381-3. Published ahead of print on 7 May 2008, doi:10.1128/JCM.00801-08.
Foster DR, Yee S, Bleske BE, Carver PL, Shea MJ, Menon SS, Ramachandran S, Welage LS, Amidon GL. Lack of Interaction Between the Peptidomimetic Substrates Captopril and Cephradine. J Clin Pcol2009;49:360-367.
Pogue JL, AlanizCA, Carver PL, Pleva M, Newton D, DePestel DD. Role of unit-specific combination antibiograms for improving the selection of appropriate empiric therapy for gram-negative pneumonia. Infection Control and Hospital Epidemiology, 2011 Mar;32(3):289-92.
Btaiche IF, Carver PL, Welch K. Dosing and Monitoring of Trace Elements in Long Term Home Parenteral Nutrition Patients. JPEN J Parenter Enteral Nutr. 2011 Nov;35(6):736-47. doi: 10.1177/0148607111413902. Epub 2011 Aug 8.
Antworth A, Collins CD, Kunapuli A, Klein K, Carver P, Gandhi T, Washer L, Nagel JL.Impact of an Antimicrobial Stewardship Program Comprehensive Care Bundle on Management of Candidemia.Pharmacotherapy 2013 Jan 25. doi: 10.1002/phar.1186. [Epub ahead of print] Selected as a ‘Top 20 Articles in Antimicrobial Stewardship, 2011 – 2013’ by the Society of Infectious Diseases Pharmacists (SIDP).
Eschenauer GA, Carver PL, Lin SW, Klinker KP, Chen YC, Potoski BA, Shields RK, Clancy CJ, Nguyen MH, Lam SW.Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study.J Antimicrob Chemother. 2013 Apr;68(4):922-6. doi: 10.1093/jac/dks482. Epub 2012 Dec 4.
Eschenauer GA, Nguyen MH, Shoham S, Vazquez J, Morris A, Pasculle W, Kubin C, KlinkerK, Carver PL, Hanson K, Chen S, Lam S, Potoski BA, Clarke L, Shields RK, Clancy CJ.Real-world experience with echinocandin MICs against Candida species: A multi-center study of hospitals that routinely perform susceptibility testing of bloodstream isolates.Antimicrob Agents Chemother 2014;58(4):1897-906.
Carver P, Kauffman CA, Srodawa A, Suchak M, King J, Candida glabrata Fungemia in an Era of Echinocandins: The Impact of Fluconazole Resistance and the Selection of Appropriate Empiric Therapy. Mycoses, submitted.
Pettit NN, DePestel DD, Fohl A, Eyler R, Carver PL. Risk Factors Associated with Systemic Absorption of Oral Vancomycin in the Treatment of Clostridium difficile infection. Pharmacotherapy, in press.
Carver PL, Veltman K. Risk factors for Candida dubliniensis fungemia. submitted.
BOOK CHAPTERS / CONTRIBUTER TO BOOK
Nightingale CH, Carver PL. Basic Principles of Pharmacokinetics. B. Gerson, ed. In: Clinics in Laboratory Medicine. Therapeutic Drug Monitoring-I. W.B. Saunders, Comp. Harcourt, Brace, Jovanovich, Inc. 1987.
Carver PL. Intra-abdominal Infections. In: Koda-Kimble MA, Young LY (eds): Applied Therapeutics: the Clinical Use of Drugs. 5th edition. Applied Therapeutics, Inc., Vancouver, Washington. 1992.
Carver PL. Fungal Infections. In: DiPiro JT, Talbot RL, Hayes PE, Yee GC, Matzke GR, Posey LM (eds): Pharmacotherapy: A Pathophysiologic Approach. 2nd edition. Appleton & Lange, NorwalkConnecticut. 1993.
Carver PL. Bacteremia and Sepsis. In: Herfindal ET, Gourley DR, Hart LL (eds): Clinical Pharmacy and Therapeutics. 5th edition. Williams and Wilkins, BaltimoreMD. 1992.
Carver PL. Respiratory Infections. In: Pharmacotherapy Self-Assessment Program (PSAP). AmericanCollege of Clinical Pharmacy. 1992.
Carver PL. Intra-abdominal Infections. In: Koda-Kimble MA, Young LY (eds): Applied Therapeutics: the Clinical Use of Drugs. 6th edition. Applied Therapeutics, Inc., Vancouver, Washington. 1995.
Carver PL. Fungal Infections. In: DiPiro JT, Talbot RL, Hayes PE, Yee GC, Matzke GR, Posey LM (eds): Pharmacotherapy: A Pathophysiologic Approach. 3rd edition. Appleton & Lange, NorwalkConnecticut. 1997.
Carver PL. Fungal Infections. In: DiPiro JT, Talbot RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds): Pharmacotherapy: A Pathophysiologic Approach. 4th edition. Appleton & Lange, NorwalkConnecticut. 1999, pg 1839-1867.
Carver PL. Fungal Infections. In: DiPiro JT, Talbot RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds): Pharmacotherapy: A Pathophysiologic Approach. 5th edition. McGraw-Hill. 2002.
Carver PL. Fungal Infections. In: DiPiro JT, Talbot RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds): Pharmacotherapy: A Pathophysiologic Approach. 6th edition. McGraw-Hill. 2005, pg 2161-90.
Carver PL. In "The Ubiquitous Roles of Cytochrome P450 Proteins", Vol. 3 of 'Metal Ions in Life Sciences'; A. Sigel, H. Sigel, R. K. O. Sigel, Eds.; John Wiley & Sons, Ltd., Chichester, UK, 2007, 3:591-617.
Carver PL. Fungal Infections. In: DiPiro JT, Talbot RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds): Pharmacotherapy: A Pathophysiologic Approach. 7th edition. 2008. McGraw-Hill.
Carver PL. Fungal Infections. In: DiPiro JT, Talbot RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds): Pharmacotherapy: A Pathophysiologic Approach. 8th edition. 2011. McGraw-Hill.
Carver PL (contributor/consultant). In: 2011 Nursing Drug Handbook. 31st edition. 2011. Walters Kluwer & Lippincott Williams & Wilkins.
Carver PL (contributor/consultant). In: Karch AM (ed). Lippincott’s 2011 Nursing Drug Guide. 2011. Walters Kluwer & Lippincott Williams & Wilkins.
Carver PL (contributor/consultant). In: 2013 Nursing Drug Handbook. 32nd edition. 2013. Walters Kluwer & Lippincott Williams & Wilkins.
Carver PL. Fungal Infections. In: DiPiro JT, Talbot RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds): Pharmacotherapy: A Pathophysiologic Approach. 9th edition. 2014. McGraw-Hill.
Carver PL (contributor/consultant). In: Karch AM (ed). Lippincott’s 2011 Nursing Drug Guide. 2013. Walters Kluwer & Lippincott Williams & Wilkins.
Carver PL. Metal Ions and Infectious Diseases. An Overview from the Clinic. in "Interrelations between Essential Metal Ions and Human Diseases", Volume 13 of 'Metal Ions in Life Sciences'; A. Sigel, H. Sigel, R. K. O. Sigel, Eds.; Springer Science & Business Media B.V., Dordrecht (The Netherlands). Met Ions Life Sci. 2013;13:1-28. doi: 10.1007/978-94-007-7500-8_1.
Carver PL (contributor/consultant). In: Nursing 2015 Drug Handbook. 33nd edition. 2015. Walters Kluwer & Lippincott Williams & Wilkins.
REVIEWS
Quintiliani R, Carver PL, NightingaleCH. The Safety of Parenteral Cephalosporins. World Med Communic Org. 1986.
Carver PL. Are Antibiotic Irrigating Solutions Effective for the Prevention or Treatment of Surgical Wound Infections? Clinical Pharmacy 1987; 6: 352, 356.
Carver PL. Pharmacokinetics of Vancomycin in Renal Failure. American Soc Clin Pathology. Check Sample Program. Clinical Pharmacology No. CP 86-6 (CP-42), 1987.
Carver PL, Colburn P. Treatment of Metronidazole-Resistant Cases of Vaginal Trichomoniasis. Clinical Pharmacy 1988; 7(10): 718-719.
Carver PL, Fekety R. The Fluoroquinolones. Consultant 1988; 28(7): 59-67.
Colburn P, Carver P. Pharmacokinetics of antibiotics in hemodialysis. Michigan Drug Letter. February 1989.
Carver PL. Clinically Relevant Drug Interactions and Adverse Effects of Antimicrobial Agents. Current Opinion in Infectious Diseases 1991;4(6):749-756.
Carver PL. Antibiotic Efficacy Review. Pharmacy Practice News Sept 1995:11-14.
KauffmanCA, Carver PL. Use of Azoles for Systemic Antifungal Therapy. Advances in Pharmacology 1997;39:143-189.
KauffmanCA, Carver PL. Antifungal Agents in the 1990s: Current Status and Future Developments. Drugs 1997;53(4):539-49.
Kaul DR, CintiSK, Carver PL, Kazanjian PH. HIV Protease Inhibitor Agents: Advances In Therapy And Adverse Reactions; Including Metabolic Complications. Pharmacotherapy 1999; 19(3): 281-98.
Carver PL. Drug Interactions in the HIV-infected Patient: Focus on Azoles and Protease Inhibitors. Pharmacoeconomics: Infectious Diseases 1999, 3(1)2-3, 6-7, 16.
Carver PL.From Macrolides to Ketolides: What is Available For The Treatment Of Outpatient Respiratory Tract Infections. Southern Medical Journal September 2002; 18-25.
Carver PL.Antifungal Therapy in the New Millenium. Clin Trends. 2002. published online Clinical Trends in Pharmacy Practice, available online at
Carver PL.Micafungin. Annals of Pharmacotherapy 2004;38:(10):1707-21.
Drew RH, on behalf of the American College of Clinical Pharmacy Infectious Diseases Practiceand Research Network Bibliography Group. Key References on Infectious Diseases Pharmacotherapy. Pharmacotherapy 2004;24(11)1586-93.
Lin SW, Carver PL, DePestel DD. Dalbavancin: A New Option for the Treatment ofGram-Positive Infections. Annals of Pharmacotherapy 2006;40:449-60.
Saad A, DePestel DD, Carver PL.Factors Influencing the Magnitude and ClinicalSignificance of Drug Interactions Between Azole Antifungals and Select Immunosuppressants. Pharmacotherapy 2006; 26(12):1730-44.
Eschenauer G, DePestel DD, Carver PL. Comparison of Echinocandin Antifungals. Therapeutics and Clinical Risk Management 2007:3(1) 71–97.
KauffmanCA, Carver PL.Update on echinocandin antifungals. Seminars in Respiratory and Critical Care Medicine2008;29(2):211-9.
Lam S, Eschenauer G, Carver PL. Evolving Role of Early Antifungal Use in the Adult Intensive Care Unit. Critical Care Medicine 2009;37(5):1583-93.
Surowiec D, DePestel DD, Carver PL. Primary Antifungal Prophylaxis in Adult Hematopoietic Stem Cell Transplant Recipients: Current Therapeutic Concepts. Pharmacotherapy, 2009;29(11):1306–25.
Eschenauer G, Lam S, Carver PL. Antifungal Prophylaxis in Liver Transplant Recipients.Liver Transplantation, 2009 Jul 29;15(8):842-858.
Jorgenson MR, DePestel DD, Carver PL. Ceftaroline: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.Annals of Pharmacotherapy,2011 Nov;45(11):1384-98. Epub 2011 Oct 18.
Eschenauer G, Carver PL. Evolving Role of Antifungal Susceptibility Testing: Has its Time Come? SIDP Newsletter, Vol 22, issue 3, July 2012.
Eschenauer G, Carver PL. Evolving Role of Antifungal Susceptibility Testing: Has its Time Come?, Pharmacotherapy. 2013 May;33(5):465-75. doi: 10.1002/phar.1233. Epub 2013 Apr 1.
This publication was selected for 2 awards: (1) featured article on (a site that reviews articles and chooses those of high value for the week), (2) selected for the Faculty of 1000 as a ‘F1000Prime’ article; it was recommended as being of special significance in its field by Faculty Member Ana Espinel-Ingroff.
Chheng ML, Carver PL, Jameson A. Acyclovir, Valacyclovir, and Valganciclovir-induced Hepatotoxicity: Case Report and Review of the Literature. submitted.
CASE REPORTS / BOOK REVIEWS / LETTERS / COMMENTARIES
Carver PL. Book Review: Handbook of Clinical Drug Data. Drug Intell Clin Pharm 1988; 22:921.